Effects of Gene Variants Controlling Vitamin D Metabolism and Serum Levels on Hepatic Steatosis

Jamka, Małgorzata; Arslanow, Anita; Bohner, A; Krawczyk, Marcin; Weber, Susanne N.; Grünhage, F; Lammert, Frank; Stokes, Caroline S.

doi:10.1159/000485180

Cited by 7 publications

(20 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 19 records were further excluded at this stage since they did not report the outcome of interest. Finally, a total of 12 studies fulfilled the eligibility criteria [20][21][22][23][24][25][26][27][28][29][30][31].…”

Section: Search Resultsmentioning

confidence: 99%

“…Interestingly, variations of genes involved in vitamin D metabolism pathway described above have been shown to be associated with many conditions, such as coronary artery disease, osteoporosis, diabetes and autoimmune diseases, indicating the interaction between this pathway and health outcomes [16][17][18][19]. Additionally, a number of studies have reported the association between vitamin D-related genetic variations and NAFLD [20][21][22][23][24][25][26][27][28][29][30][31]. The objective of this systematic review was therefore to identify and summarize the results of all available studies that explored the association of vitamin D-related genetic polymorphisms with presence, severity and response to treatment of NAFLD.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vitamin D-related Genetic Variations and Non-alcoholic Fatty Liver Disease: a Systematic Review

Jaroenlapnopparat¹,

Suppakitjanusant²,

Ponvilawan³

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Studies have demonstrated the link between vitamin D-related genetic variations and non-skeletal outcomes. We aimed to identify all available data on the association of vitamin D-related genetic variations with non-alcoholic fatty liver disease (NAFLD). Methods: Potentially eligible studies were identified from Embase and Medline databases from inception to June 2022 using search strategy that comprised terms for “Vitamin D” and “NAFLD”. Eligible study must report the association between vitamin D-related genetic variations and presence, severity or response to treatment of NAFLD. Data were extracted from each eligible study. Results: A total of 3,495 articles were identified. After systematic review, twelve studies were in-cluded. A total of 26 genetic variations were identified. Presence of NAFLD was associated with variations of GC (rs222054, rs222020, rs10011000, rs7041), VDR (rs2228570, rs11168287, rs10783219, rs4752), CYP24A1 (rs3787557, rs6068816, rs2296241, rs2248359) and CYP27B1 (rs4646536). Severity of NAFLD was associated with variations of GC (rs4588), VDR (rs2228570, rs4334089), CYP2R1 (rs10741657), DHCR7 (rs1544410, rs3829251, rs12785878) and CYP24A1 (rs3787557, rs6068816, rs6097809, rs6127119, rs2248359, rs3787554, rs4809960, rs6022999). Response to calcitriol treatment was associated with variation of VDR (rs10735810). Conclusions: Multiple vitamin D-related genetic variations were associated with NAFLD, indi-cating the role of vitamin D in the pathogenesis of NAFLD.

show abstract

Section: Search Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Vitamin D-related Genetic Variations and Non-alcoholic Fatty Liver Disease: a Systematic Review

Jaroenlapnopparat¹,

Suppakitjanusant²,

Ponvilawan³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…In the current study, there were only nine cases with chronic C hepatitis, including six cases associated with hepatocellular carcinoma. For patients with vitamin D deficiency, recent studies have suggested that a genetic relationship between patients with VDR and CYP2R1 gene variants may be linked to the deficiency [ 11 , 12 ]. Our recent study showed that VDR rs2228530 genetic alleles with AA and AG may be associated with the development of non-alcoholic fatty liver disease after LDLT [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

Liver Graft Pathology and Low Serum 25-Hydroxyvitamin D after Living Donor Liver Transplantation

et al. 2022

View full text Add to dashboard Cite

Background: Most cases of advanced liver diseases are associated with low serum 25-hydroxyvitamin D and vitamin D deficiency. This phenomenon may occur in living donor liver transplantation (LDLT). Aims: We conducted this study to explore the interplay between VDR and CYP2R1 in liver graft and compared our findings with the pathological interpretation of serum 25(OH)D concentration. Methods: In total, 60 patients received liver graft biopsy after LDLT and were separated (1:1) into two groups: graft rejection group and graft non-rejection group. We extracted both of the recipients’ and donors’ serum DNA to investigate the vitamin D receptor (VDR) rs2228530 and CYP2R1 rs10741657 single nucleotide polymorphisms (SNPs) using real-time polymerase chain reaction. We also extracted DNA from liver graft tissues to explore the genetic alleles of VDR rs2228530 and CYP2R1 rs10741657 after LDLT. Serum biochemistry profile and 25(OH)D concentrations were measured before and after LDLT. Results: There were no significant differences in serum VDR rs2228530 and CYP2R1 rs10741657 genetic alleles between recipients and donors. The percentage of genetic modification was 33.4% (10/30) for the rejection and non-rejection groups in VDR rs2228530, and 66.7% (20/30) for both groups in CYP2R1 rs10741657. Serum 25(OH)D concentrations were significantly lower after LDLT D30 than that before LDLT in the rejection (p = 0.0001) and non-rejection graft pathology (p = 0.0017) groups. Conclusions: The presence of low serum 25(OH)D concentrations after LDLT suggested that post-transplant low serum 25(OH)D concentrations may develop with the homogenous phenomenon of VDR rs2228530 and CYP2R1 rs10741657 genetic modifications in recipients regardless of graft pathology.

show abstract

“…Interestingly, Levels of ALT is usually a marker of hepatocellular injury [ 43 ]. However, levels of blood biochemical indexes, like ALT, AST, ALP, GGT, and TBIL, are not able to predict NC-induced liver injury in our study.…”

Section: Discussionmentioning

confidence: 99%

Quantified MRI and 25OH-VitD3 can be used as effective biomarkers for patients with neoadjuvant chemotherapy-induced liver injury in CRCLM?

Wang

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: To evaluate proton-density fat-fraction (PDFF) and intravoxel incoherent motion (IVIM) techniques, and human 25-hydroxyvitamin D3 (25OH-VitD3) levels, as potential biomarkers in patients with colorectal cancer with liver metastasis (CRCLM). Changes were compared with those related to chemotherapy-associated steatohepatitis (CASH) and sinusoidal obstruction syndrome (SOS). Methods: 63 patients with pathologically confirmed colorectal adenocarcinoma received 4-6 courses of NC before liver resection and underwent magnetic resonance imaging (MRI) with iterative decomposition of water and fat with echo asymmetry and least-squares estimation quantification and IVIM sequences. Blood samples were analyzed using CTCAE. Pathological changes of liver tissues outside the metastases were assessed as the gold standard, and receiver operating characteristic (ROC) curves were analyzed. Results: 16 cases had CASH liver injury, 14 cases had SOS changes, and 4 cases had CASH and SOS, and 7 showed no significant changes. Consistency between biochemical indices and pathological findings was poor (kappa = 0.246, p = 0.005). The areas under the ROC curve (AUCs) of ALT, AST, ALP, GGT, and TBIL were 0.571-0.691. AUCs of D, FF, and 25OH-VitD3 exceeded 0.8; when considering these markers together, sensitivity was 85.29% and specificity was 93.13%. ANOVA showed statistically significant differences among D, FF, and 25OH-VitD3 for different grades of liver injury (F = 4.64-26.5, p = 0.000-0.016). Conclusions: D, FF, and 25OH-VitD3 are biomarkers for accurate prediction of NC-induced liver injury in patients with CRCLM, while FF and 25OH-VitD3 might be beneficial to distinguish liver injury grades. Trial registration: Current Trials was retrospectively registered as ChiCTR1800015242 at Chinese Clinical Trial Registry on March 16, 2018.

show abstract

Effects of Gene Variants Controlling Vitamin D Metabolism and Serum Levels on Hepatic Steatosis

Cited by 7 publications

References 44 publications

Vitamin D-related Genetic Variations and Non-alcoholic Fatty Liver Disease: a Systematic Review

Vitamin D-related Genetic Variations and Non-alcoholic Fatty Liver Disease: a Systematic Review

Liver Graft Pathology and Low Serum 25-Hydroxyvitamin D after Living Donor Liver Transplantation

Quantified MRI and 25OH-VitD3 can be used as effective biomarkers for patients with neoadjuvant chemotherapy-induced liver injury in CRCLM?

Contact Info

Product

Resources

About